Clinical Trial Update: Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 safety study evaluating lenalidomide maintenance after allogeneic hematopoietic cell transplantation in high-risk multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: Center for International Blood and Marrow Transplant Research | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED